Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A clinical study to assess next-day driving performance following evening administrations of ACT-541468 in middle-aged and elderly subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment A (50 mg ACT-541468) | Experimental | 1 tablet of ACT-541468 50 mg + 1 tablet of ACT-541468 matching placebo + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period A. |
|
| Treatment B (100 mg ACT-541468) | Experimental | 2 tablets of ACT-541468 50 mg + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period B. |
|
| Treatment C (7.5 mg zopiclone) | Experimental | 2 tablets of ACT-541468 matching placebo + 1 capsule of zopiclone 7.5 mg administered in the evening on Days 1 and 4 of Treatment Period C. In the evenings of Days 2 and 3, subjects will receive placebo (i.e., 2 tablets of ACT-541468 matching placebo + zopiclone matching placebo). |
|
| Treatment D (placebo) | Experimental | 2 tablets of ACT-541468 matching placebo + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period D. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ACT-541468 | Drug | Film-coated tablet for oral use at a dose strength of 50 mg. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacodynamic endpoint: Driving performance as measured by the SDLB (difference from placebo, cm) using the Green Dino driving simulator - Day 2 | SDLP = standard deviation of the lateral position | On Day 2 at 9 hours post dose. Duration of the test: 1 hour |
| Pharmacodynamic endpoint: Driving performance as measured by the SDLB (difference from placebo, cm) using the Green Dino driving simulator - Day 5 | SDLP = standard deviation of the lateral position | On Day 5 at 9 hours post dose. Duration of the test: 1 hour |
Not provided
Not provided
Inclusion Criteria
General criteria:
Study-specific criteria
Exclusion Criteria:
General criteria:
Study-specific criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Pharmacologist | Idorsia Pharmaceuticals Ltd. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre for Human Drug Research | Leiden | 2333 | Netherlands |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C000634383 | daridorexant |
| C515050 | zopiclone |
Not provided
Not provided
Not provided
4-way cross-over study
Not provided
Not provided
Not provided
| Zopiclone 7.5 mg | Drug | Over-encapsulated to maintain blinding. |
|
| Placebo | Other | Matching to maintain blinding. |
|